Table 1. Demographic and clinical data for patients who donated intestinal samples analyzed in the study
Sample typeGenderTissueAge (yr)DiagnosisIBD medication
Healthy (non-IBD) samples
ResectionsMaleColon73Sigmoid colon cancerN/A
MaleColon73Concurrent bladder and rectal cancerN/A
FemaleColon74Sigmoid adenocarcinomaN/A
MaleColon75Colorectal cancer with liver metastasesN/A
FemaleColon63Caecal tumor and bladder tumorN/A
FemaleColon73AdenocarcinomaN/A
MaleColon64AdenocarcinomaN/A
MaleColon64AdenocarcinomaN/A
FemaleColon51Colon cancer with metastasesN/A
MaleColon40Rectal carcinoma with metastasesN/A
MaleRectum67Rectal carcinomaN/A
FemaleColon57Colon cancer with metastasesN/A
FemaleColon61Colonic polypN/A
BiopsiesMaleColon46Healthy (screen for cancer)N/A
FemaleColon61Healthy (screen for cancer)N/A
MaleColon79Healthy (screen for cancer)N/A
IBD patients
ResectionsFemaleColon31Active Crohn’s diseaseAzathioprine
FemaleColon21Active Crohn’s diseaseVedolizumab, prednisolone
MaleColon25Active Crohn’s diseaseInfliximab, methotrexate
FemaleColon47Active Crohn's diseasePrednisolone, simethicone
FemaleColon59Active Crohn’s diseaseAzathioprine, adalimumab, methotrexate
MaleColon51Active ulcerative colitisAdalimumab
MaleColon25Active ulcerative colitisAzathioprine, mesalazine
BiopsiesMaleRectum25Active Crohn’s diseaseAdalimumab, methotrexate
FemaleColon23Active Crohn’s diseaseInfliximab
MaleRectum17Active ulcerative colitisInfliximab
MaleRectum57Active ulcerative colitisPrednisone, omeprazole, mesalazine

N/A, not applicable.